international regulations there are only 2 problems with this trial 1st it was not published yet and sakho are. of 40 people as far as their own number 40 that can be a little bit small 0 based on my experience it is a reasonably appropriate phase one trial that is compliant because global legislations is there anything at this stage that could go wrong. absolutely a live accent is a risk here and this is the reason why you can't europe and us deal a reduced creation because there are risks and at some point you will ask me so how could it happen that russia is the 1st it was because russian government is running cropper pharmaco canonical analysis that accounts not only for people that may have fascination risks but also for people who have hardships related to sell for a solution and all kind of. they mean a regulations russia is going to take this is going to say russia is usually top of the game when it comes to spy and some medicine what does it mean that it's being registered here for the general public like us it just means it's a step forward towards it being used on the public or